Modern medicine moves ever more to precision, personalised medicine, and precision dosing is critical in a world that ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to ...

Since the start of the year, Ipsen has bolstered its oncology pipeline with two ADC alliances – with Foreseen Bio and Sutro ...

The Northern Ireland Protocol (NIP) that kept NI within the EU pharma regulatory system was widely derided for failing to ...

Cost-effectiveness agency NICE has recommended NHS use of the therapy – called Kimmtrak (tebentafusp) – for the treatment of ...

"A prerequisite for Orexo to succeed with a sophisticated digital health product like Deprexis is a tight collaboration with ...

Venture capital group Abingworth is reportedly trying to raise up to $1.5 billion in investment funding to support biopharma ...

Today, 36 million people in the European Union (EU) and 30 million in the US with a rare disease face the harsh reality of a ...

Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics ...

In a post on X.com, Neuralink said it had been granted regulatory approval for "a new feasibility trial to extend BCI control ...

Alligator – which has developing mitazalimab on its own after losing Johnson & Johnson as a partner for the drug a few years ...